Cardiac Shock Wave Therapy Reduces Angina and Improves Myocardial Function in Patients With Refractory Coronary Artery Disease

Background: Safe and effective therapeutic management of refractory coronary artery disease (CAD) in heart patients is critical to enhance cardiovascular function and improve quality of life. Current therapies for refractory CAD are inadequate in ameliorating angina and promoting revascularization o...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cardiology (Mahwah, N.J.) N.J.), 2010-11, Vol.33 (11), p.693-699
Main Authors: Wang, Yu, Guo, Tao, Cai, Hong‐Yan, Ma, Tie‐Kun, Tao, Si‐Ming, Sun, Shuai, Chen, Ming‐Qing, Gu, Yun, Pang, Jia‐Hua, Xiao, Jian‐Ming, Yang, Xi‐Yun, Yang, Chao
Format: Article
Language:English
Subjects:
Aged
Angina Pectoris - etiology
Angina Pectoris - physiopathology
Angina Pectoris - therapy
Angioplasty, Balloon, Coronary - instrumentation
Biological and medical sciences
Cardiology. Vascular system
China
Clinical Investigations
Coronary Artery Disease - complications
Coronary Artery Disease - physiopathology
Coronary Artery Disease - therapy
Coronary Circulation
Coronary heart disease
Echocardiography, Stress
Heart
High-Energy Shock Waves - therapeutic use
Humans
Male
Medical sciences
Middle Aged
Myocardial Contraction
Myocardial Ischemia - etiology
Myocardial Ischemia - physiopathology
Myocardial Ischemia - therapy
Nitroglycerin - administration & dosage
Pilot Projects
Radionuclide Angiography
Recovery of Function
Stents
Systole
Time Factors
Tomography, Emission-Computed, Single-Photon
Treatment Outcome
Vasodilator Agents - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Safe and effective therapeutic management of refractory coronary artery disease (CAD) in heart patients is critical to enhance cardiovascular function and improve quality of life. Current therapies for refractory CAD are inadequate in ameliorating angina and promoting revascularization of ischemic myocardium. Hypothesis: Cardiac shock wave therapy (CSWT) is a safe and effective noninvasive intervention in the management of patients with refractory CAD. Methods: The study enrolled 9 male patients age 50 to 70 years (5.11 ± 5.46 years) with a diagnosis of CAD and stent implantation (3.00 ± 2.24 stents). CSWT was carried out for 3 months at 3 intervals during the first week of each month (first, third, and fifth day), for a total of 9 therapies per patient. Dobutamine stress echocardiography and radionuclide angiography identified the myocardial ischemic segments. The effects of CSWT on myocardial perfusion and systolic function were examined. Other outcome measures included myocardial injury enzyme markers, angina scale, nitroglycerin dosage, and cardiopulmonary fitness assessments. Results: Improved myocardial blood flow and regional systolic function (stress peak systolic strain rate − 1.10 to − 1.60 s−1, P = 0.002) were detected in patients following CSWT. Reductions in creatine kinase (87.89 ± 36.69 to 86.22 ± 35.96 IU/L, P = 0.046), creatine kinase MB (10.89 ± 5.73 to 10.11 ± 5.93 IU/L, P = 0.008), aspartate transaminase (interquartile range [IQR], 28.00 to 27.00 IU/L, P = 0.034) were also found. Angina (Canadian Cardiovascular Society scale IQR 3.0 to 2.0, P = 0.035) and nitroglycerin dose reduction (IQR 3.0 to 1.0 times/wk, P = 0.038) were reported. Conclusions: This study is a preliminary assessment of CSWT in patients with refractory CAD. We report that CSWT is a noninvasive, effective, and safe intervention in the treatment of refractory CAD. Copyright © 2010 Wiley Periodicals, Inc. The authors have no funding, financial relationships, or conflicts of interest to disclose.
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.20811